EmailFacebookLinkedInTwitterGoogle+
Oxford Biotheraputics
News
News

Oxford BioTherapeutics provides regular updates of our R&D, scientific and corporate progress through regular conference presentations, scientific journal publications and press releases. For more information please contact us directly.

02/10/2014 News

The OBT / Menarini partnership has been cited in the September issue of Nature’s BioPharma Dealmakers as the second most significant antibody and ADC technology platform deals over $100m total deal value between Jan 2009–July 2014.

09/02/2017 Press Release

Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

26/01/2017 Press Release

Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics

18/04/2016 Press Release

Boehringer Ingelheim exercises option on second oncology target using Oxford BioTherapeutics’ OGAP® system

04/04/2016 Press Release

Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates

08/10/2015 Press Release

Oxford BioTherapeutics Appoints Shawn Tomasello to its Board of Directors  

30/07/2015 Press Release

Oxford BioTherapeutics receives $10 million capital term loan from Silicon Valley Bank  

23/02/2015 Press Release

Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston

14/01/2015 Press Release

Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to an Oncology Target

25/11/2014 Press Release

$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia

02/10/2014 Press Release

Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

08/07/2014 Press Release

Oxford BioTherapeutics Appoints Eugen Leo MD PhD MBA as Head of Clinical Development

18/06/2014 Press Release

Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer  

07/05/2014 Press Release

Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Novel Antibody-Drug Conjugate for HER2-Negative Breast Cancer

16/01/2014 Press Release

Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors

09/12/2013 Press Release

Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance

26/06/2013 Press Release

Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman

29/04/2013 Press Release

Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer

29/10/2012 Press Release

Menarini Group and Oxford BioTherapeutics Collaborate for Development and Manufacture of Novel Antibody-Based Cancer Drugs

02/05/2012 Press Release

Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland

11/01/2012 Press Release

Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director

13/09/2011 Press Release

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

09/09/2011 Press Release

CMC Biologics Licenses its CHEF1® Expression System to Oxford BioTherapeutics

02/09/2011 Press Release

Oxford BioTherapeutics licenses Lonza′s GS Gene Expression System™

06/04/2011 Press Release

Oxford BioTherapeutics Licenses BioWa′s POTELLIGENT® Technology for the Research and of its Therapeutic Antibodies in Cancer

25/01/2011 Press Release

Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers

2004 - 2010